Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/ofid/ofw249 http://scihub22266oqcxt.onion/10.1093/ofid/ofw249 C5414114!5414114 !28480245     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28480245 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Open+Forum+Infect+Dis 2017 ; 4 (1 ): ofw249 Nephropedia Template TP {{tp|p=28480245 |t=2017. Using Procalcitonin to Guide Antibiotic Therapy |pdf=|usr=}}{{28480245 }} gab.com Text Using Procalcitonin to Guide Antibiotic Therapy JO: Open Forum Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=28480245 #FOAvip Procalcitonin levels rise in response to systemic inflammation, especially of bacterial origin. Multiple randomized controlled trials have demonstrated that procalcitonin-based algorithms can safely reduce antibiotic use in 2 clinical scenarios. First, in stable, low-risk patients with respiratory infections, procalcitonin levels of <0.25 µg/L can guide the decision to withhold antibiotics or stop therapy early. Second, in critically ill patients with suspected sepsis, clinicians should not initially withhold antibiotics, but procalcitonin levels of <0.5 µg/L or levels that decrease by ?80% from peak can guide discontinuation once patients stabilize. The recent stop antibiotics on procalcitonin guidance study (SAPS), the largest procalcitonin trial to date, demonstrated reduction in both antibiotic exposure and mortality in critically ill patients. Although procalcitonin is ready for routine use, future research should examine optimal strategies for implementation in hospitals, its real-world impact on clinical outcomes and costs, its applicability to immunocompromised patients, and the generalizability of trials to the US population. Twit Text FOAVip Using Procalcitonin to Guide Antibiotic Therapy ????Open Forum Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=28480245 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28480245 #FOAvip English Wikipedia <ref>{{Cite pmid|28480245 }}</ref> Using Procalcitonin to Guide Antibiotic Therapy #MMPMID28480245 Rhee C Open Forum Infect Dis 2017[Win]; 4 (1 ): ofw249 PMID28480245 show ga Procalcitonin levels rise in response to systemic inflammation, especially of bacterial origin. Multiple randomized controlled trials have demonstrated that procalcitonin-based algorithms can safely reduce antibiotic use in 2 clinical scenarios. First, in stable, low-risk patients with respiratory infections, procalcitonin levels of <0.25 µg/L can guide the decision to withhold antibiotics or stop therapy early. Second, in critically ill patients with suspected sepsis, clinicians should not initially withhold antibiotics, but procalcitonin levels of <0.5 µg/L or levels that decrease by ?80% from peak can guide discontinuation once patients stabilize. The recent stop antibiotics on procalcitonin guidance study (SAPS), the largest procalcitonin trial to date, demonstrated reduction in both antibiotic exposure and mortality in critically ill patients. Although procalcitonin is ready for routine use, future research should examine optimal strategies for implementation in hospitals, its real-world impact on clinical outcomes and costs, its applicability to immunocompromised patients, and the generalizability of trials to the US population. äUsing Procalcitonin to Guide Antibiotic Therapy (epmc).pdf DeepDyve Pubget Overpricing